SCHEMBL2389964

SCHEMBL2389964

O=C(O)c1cc2ccc(OS(=O)(=O)C(F)(F)F)cc2oc1=O

nearest known ligand 0.81

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD11B1 P28845 1/20 0.81
SLC16A3 O15427 6/20 0.65
MAOB P27338 5/20 0.56
CA12 O43570 3/20 0.56
CA1 P00915 3/20 0.56
CA5A P35218 3/20 0.56
CA7 P43166 3/20 0.56
CA5B Q9Y2D0 3/20 0.56
CA4 P22748 2/20 0.56
CA2 P00918 2/20 0.56
CA3 P07451 2/20 0.51
CA6 P23280 2/20 0.51
CA9 Q16790 2/20 0.51
CA14 Q9ULX7 2/20 0.51
TSHR P16473 1/20 0.51
GPR35 Q9HC97 1/20 0.51
ALDH1A1 P00352 4/20 0.51
HPGD P15428 3/20 0.51
KDM4E B2RXH2 3/20 0.51
GAA P10253 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2391806 0.85 HSD11B1 (0.73) HSD11B1MAOBCA12CA1CA5A
SCHEMBL17179737 0.81 HSD11B1 (0.69) HSD11B1SLC16A3MAOBCA12CA1
SCHEMBL17179661 0.81 HSD11B1 (0.65) HSD11B1SLC16A3MAOBCA12CA1
SCHEMBL203997 0.79 SLC16A3 (1.00) HSD11B1SLC16A3MAOBCA12CA1
SCHEMBL28521513 0.79 HSD11B1 (0.62) HSD11B1SLC16A3MAOBCA12CA1
SCHEMBL21761480 0.78 NPC1 (0.66) HSD11B1MAOBALDH1A1HPGDKDM4E
SCHEMBL9432106 0.77 GLA (0.68) HSD11B1MAOBCA12CA1CA5A
SCHEMBL31222311 0.77 SLC16A3 (0.74) HSD11B1SLC16A3MAOBCA12CA1
SCHEMBL93281 0.77 SLC16A3 (0.70) SLC16A3MAOBCA12CA1CA5A
SCHEMBL4101829 0.77 SLC16A3 (0.74) HSD11B1SLC16A3MAOBCA12CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-RE42700-E1 Induction of apoptosis in cancer cells SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) 2011-09-13 US disclosed
US-7053071-B2 For therapy of leukemia or other forms of cancer or for treating disease conditions caused by apoptosis of cells THE BURNHAM INSTITUTE (US) 2006-05-30 US disclosed
EP-1456165-A1 INDUCTION OF APOPTOSIS IN CANCER CELLS The Burnham Institute (US) 2004-09-15 EP disclosed
US-20030176506-A1 Induction of apoptosis in cancer cells BURNHAM INSTITUTE FOR MEDICAL RESEARCH 2003-09-18 US disclosed
WO-2003048101-A1 INDUCTION OF APOPTOSIS IN CANCER CELLS THE BURNHAM INSTITUTE (US) 2003-06-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030176506-A1 Induction of apoptosis in cancer cells MCL1, BAD, BCL2 HSD11B1 3297/4885SLC16A3 4489/4885MAOB 4640/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.